ArticleFrontiers in oncology2021

Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.

Meng Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.